This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT04867785 |
|---|---|
| Status | Completed |
| Phase | Phase 2 |
| Sponsor | Eli Lilly and Company |
| Enrollment | 281 participants |
| Design | Interventional, Randomized, Parallel, Masking: Double |
| Conditions | Type 2 Diabetes |
| Interventions | LY3437943; Dulaglutide; Placebo |
| Start | May 13, 2021 |
| Primary completion | Jul 8, 2022 |
| Study completion | Oct 27, 2022 |
| Results posted | Yes, in the registry |
| Registry last updated | Jul 3, 2023 |
Compounds on this site that cite this trial
What the registry says the trial is about
The main purpose of this study is to evaluate the efficacy and safety of LY3437943 in participants with type 2 diabetes (T2D) who failed to achieve adequate glycemic control on diet and exercise alone or on a stable dose of metformin. This study will last about 43 weeks.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Change From Baseline in Hemoglobin A1c (HbA1c) | Baseline, 24 Weeks |
9 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Oct 3, 2026. See the trial changes feed for what has changed recently.
